Literature DB >> 7634585

Natural history of muscle weakness in Friedreich's Ataxia and its relation to loss of ambulation.

M Beauchamp1, H Labelle, M Duhaime, J Joncas.   

Abstract

From 1979 to 1992, 170 muscular assessments performed on 33 patients with Friedreich's Ataxia were reviewed. The average followup was 6 years. All muscle evaluations were done by the same team. It was possible to delineate a fairly regular and statistically significant pattern of slowly progressive and symmetrical loss of strength affecting mainly the lower limbs, and more specifically the pelvic girdle muscles. The first significant weakness was observed in the hip extensor group, followed in a variable fashion by other muscle groups of the lower limb. Upper limb and trunk muscles remained relatively spared until late in the disease process, with an overall strength approximately 80% of normal. Use of a wheelchair began at a mean age of 18.2 years, at which time the lower-limb strength averaged 70% of normal. Patients became totally unable to walk at a mean of age 20.5 years old, with a further decline in lower limb strength to 56% of normal. Weakness does not appear to be the primary cause for loss of ambulation in patients with Friedreich's ataxia.

Entities:  

Mesh:

Year:  1995        PMID: 7634585

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  9 in total

Review 1.  Friedreich ataxia: the clinical picture.

Authors:  Massimo Pandolfo
Journal:  J Neurol       Date:  2009-03       Impact factor: 4.849

Review 2.  Diagnosis and treatment of Friedreich ataxia: a European perspective.

Authors:  Jörg B Schulz; Sylvia Boesch; Katrin Bürk; Alexandra Dürr; Paola Giunti; Caterina Mariotti; Francoise Pousset; Ludger Schöls; Pierre Vankan; Massimo Pandolfo
Journal:  Nat Rev Neurol       Date:  2009-04       Impact factor: 42.937

3.  Demographic and clinical features and rehabilitation outcomes of patients with Friedreich ataxia: A retrospective study.

Authors:  MeryemAslan Doğan-Aslan; SıdıkaŞen Büyükvural-Şen; Güldal Funda Nakipoğlu-Yüzer; Neşe Özgirgin
Journal:  Turk J Phys Med Rehabil       Date:  2018-02-22

4.  Dimethyl fumarate dose-dependently increases mitochondrial gene expression and function in muscle and brain of Friedreich's ataxia model mice.

Authors:  Chun Kiu Hui; Elena N Dedkova; Claire Montgomery; Gino Cortopassi
Journal:  Hum Mol Genet       Date:  2021-02-25       Impact factor: 5.121

5.  Probing the kinetic stabilities of Friedreich's ataxia clinical variants using a solid phase GroEL chaperonin capture platform.

Authors:  Ana R Correia; Subhashchandra Naik; Mark T Fisher; Cláudio M Gomes
Journal:  Biomolecules       Date:  2014-10-20

6.  Rare diseases: matching wheelchair users with rare metabolic, neuromuscular or neurological disorders to electric powered indoor/outdoor wheelchairs (EPIOCs).

Authors:  Lorraine H De Souza; Andrew O Frank
Journal:  Disabil Rehabil       Date:  2015-12-30       Impact factor: 3.033

7.  Mitofusin-Dependent ER Stress Triggers Glial Dysfunction and Nervous System Degeneration in a Drosophila Model of Friedreich's Ataxia.

Authors:  Oliver Edenharter; Stephan Schneuwly; Juan A Navarro
Journal:  Front Mol Neurosci       Date:  2018-03-06       Impact factor: 5.639

Review 8.  Impact of Drosophila Models in the Study and Treatment of Friedreich's Ataxia.

Authors:  Véronique Monnier; Jose Vicente Llorens; Juan Antonio Navarro
Journal:  Int J Mol Sci       Date:  2018-07-07       Impact factor: 5.923

9.  Bioenergetics of the calf muscle in Friedreich ataxia patients measured by 31P-MRS before and after treatment with recombinant human erythropoietin.

Authors:  Wolfgang Nachbauer; Sylvia Boesch; Rainer Schneider; Andreas Eigentler; Julia Wanschitz; Werner Poewe; Michael Schocke
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.